Sphere gets regulatory OK for manufacturing products in U.K. facility

Sphere Medical has received a regulatory sign-off to make its monitoring and diagnostic products, including the Proxima arterial blood analyser, at its manufacturing facility in Harston, near Cambridge, U.K., the company notes in a release.

The U.K. company is developing a range of monitoring and diagnostic products to help in patient management. Sphere expects its products to allow near real-time measurement of blood gases, various electrolytes, glucose and drug levels at the patient's bedside. This information can enable faster clinical decision-making and improve patient outcomes, the company notes on its website.

Sphere previously had IS13485 authorization for the design and development of medical devices at the Harston facility, Proactive Investors UK notes.

"The successful completion of the audit and certification by TÜV SÜD, our notified body, validates the excellent quality management system which we have at Sphere Medical. This scope extension is an important achievement and underpins our capability for commercial manufacture at our Harston facility," said CEO Stuart Hendry in a statement.

- get the Sphere release
- here's the scoop from Proactive Investors
- check out the story from Business Weekly

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.